ImmunityBio (IBRX) EBITDA Margin (2014 - 2026)
ImmunityBio (IBRX) posted quarterly EBITDA Margin of 157.88% for Q1 2026, up 23220.0% year-over-year from N/an in Q1 2025, and up 6.55% quarter-over-quarter from 168.95% in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) EBITDA Margin (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported EBITDA Margin for 13 consecutive years, with 157.88% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 23220.0% year-over-year to 157.88%; the TTM figure through Mar 2026 stood at 185.41% (up 81841.0% YoY), while the FY2025 annual figure was 226.0%, up 210823.0% from the prior year.
- EBITDA Margin improved to 157.88% in Q1 2026 per IBRX's latest filing, from 168.95% in the prior quarter.
- Across five years, EBITDA Margin topped out at 157.88% in Q1 2026 and bottomed at 685514.29% in Q1 2022.
- Historically, EBITDA Margin has averaged 103232.55% across 5 years, with a median of 30994.44% in 2023.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 62345385 bps — and 2023, when it soared 65451984 bps.
- ImmunityBio's EBITDA Margin stood at 116301.37% in 2022, then jumped by 47 bps to 61430.94% in 2023, then soared by 99 bps to 918.96% in 2024, then jumped by 82 bps to 168.95% in 2025, then increased by 7 bps to 157.88% in 2026.
- Business Quant data shows IBRX's EBITDA Margin at 157.88% in Q1 2026, 168.95% in Q4 2025, and 173.51% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.36% |
| 10 | ImmunityBio | 8.48 Bn | 8.12 Bn | 50.94 Mn | -120.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -120.41% |
| Mar 31, 2026 | -157.88% |
| Dec 31, 2025 | -168.95% |
| Sep 30, 2025 | -173.51% |
| Jun 30, 2025 | -269.76% |
| Mar 31, 2025 | -390.08% |
| Dec 31, 2024 | -918.96% |
| Sep 30, 2024 | -1,314.33% |
| Jun 30, 2024 | -9,487.39% |
| Mar 31, 2024 | -237,990.00% |
| Dec 31, 2023 | -61,430.94% |
| Sep 30, 2023 | -97,726.83% |
| Jun 30, 2023 | -207,670.73% |
| Mar 31, 2023 | -30,994.44% |
| Dec 31, 2022 | -116,301.37% |
| Sep 30, 2022 | -76,952.54% |
| Jun 30, 2022 | -227,491.43% |
| Mar 31, 2022 | -685,514.29% |
| Dec 31, 2021 | -20,326.67% |
| Sep 30, 2021 | -119,448.48% |